全文获取类型
收费全文 | 2716篇 |
免费 | 249篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 118篇 |
妇产科学 | 87篇 |
基础医学 | 316篇 |
口腔科学 | 153篇 |
临床医学 | 313篇 |
内科学 | 370篇 |
皮肤病学 | 20篇 |
神经病学 | 168篇 |
特种医学 | 192篇 |
外科学 | 393篇 |
综合类 | 96篇 |
预防医学 | 276篇 |
眼科学 | 71篇 |
药学 | 264篇 |
中国医学 | 27篇 |
肿瘤学 | 109篇 |
出版年
2021年 | 53篇 |
2020年 | 28篇 |
2019年 | 39篇 |
2018年 | 57篇 |
2017年 | 43篇 |
2016年 | 38篇 |
2015年 | 57篇 |
2014年 | 91篇 |
2013年 | 133篇 |
2012年 | 122篇 |
2011年 | 132篇 |
2010年 | 87篇 |
2009年 | 65篇 |
2008年 | 136篇 |
2007年 | 132篇 |
2006年 | 126篇 |
2005年 | 86篇 |
2004年 | 89篇 |
2003年 | 67篇 |
2002年 | 96篇 |
2001年 | 54篇 |
2000年 | 53篇 |
1999年 | 54篇 |
1998年 | 72篇 |
1997年 | 50篇 |
1996年 | 32篇 |
1995年 | 31篇 |
1994年 | 23篇 |
1993年 | 30篇 |
1992年 | 26篇 |
1991年 | 32篇 |
1990年 | 30篇 |
1989年 | 31篇 |
1988年 | 36篇 |
1987年 | 29篇 |
1986年 | 39篇 |
1985年 | 34篇 |
1984年 | 45篇 |
1983年 | 28篇 |
1982年 | 36篇 |
1981年 | 28篇 |
1980年 | 42篇 |
1979年 | 31篇 |
1978年 | 37篇 |
1977年 | 35篇 |
1976年 | 22篇 |
1974年 | 37篇 |
1973年 | 29篇 |
1972年 | 22篇 |
1971年 | 22篇 |
排序方式: 共有2983条查询结果,搜索用时 15 毫秒
991.
Nicholas A. Malmquist Sandeep Sundriyal Joachim Caron Patty Chen Benoit Witkowski Didier Menard Rossarin Suwanarusk Laurent Renia Francois Nosten María Belén Jiménez-Díaz I?igo Angulo-Barturen María Santos Martínez Santiago Ferrer Laura M. Sanz Francisco-Javier Gamo Sergio Wittlin Sandra Duffy Vicky M. Avery Andrea Ruecker Michael J. Delves Robert E. Sinden Matthew J. Fuchter Artur Scherf 《Antimicrobial agents and chemotherapy》2015,59(2):950-959
Current antimalarials are under continuous threat due to the relentless development of drug resistance by malaria parasites. We previously reported promising in vitro parasite-killing activity with the histone methyltransferase inhibitor BIX-01294 and its analogue TM2-115. Here, we further characterize these diaminoquinazolines for in vitro and in vivo efficacy and pharmacokinetic properties to prioritize and direct compound development. BIX-01294 and TM2-115 displayed potent in vitro activity, with 50% inhibitory concentrations (IC50s) of <50 nM against drug-sensitive laboratory strains and multidrug-resistant field isolates, including artemisinin-refractory Plasmodium falciparum isolates. Activities against ex vivo clinical isolates of both P. falciparum and Plasmodium vivax were similar, with potencies of 300 to 400 nM. Sexual-stage gametocyte inhibition occurs at micromolar levels; however, mature gametocyte progression to gamete formation is inhibited at submicromolar concentrations. Parasite reduction ratio analysis confirms a high asexual-stage rate of killing. Both compounds examined displayed oral efficacy in in vivo mouse models of Plasmodium berghei and P. falciparum infection. The discovery of a rapid and broadly acting antimalarial compound class targeting blood stage infection, including transmission stage parasites, and effective against multiple malaria-causing species reveals the diaminoquinazoline scaffold to be a very promising lead for development into greatly needed novel therapies to control malaria. 相似文献
992.
Treatment of hypovitaminosis D in infants and toddlers 总被引:2,自引:0,他引:2
Gordon CM Williams AL Feldman HA May J Sinclair L Vasquez A Cox JE 《The Journal of clinical endocrinology and metabolism》2008,93(7):2716-2721
CONTEXT: Hypovitaminosis D appears to be on the rise in young children, with implications for skeletal and overall health. OBJECTIVE: The objective of the study was to compare the safety and efficacy of vitamin D2 daily, vitamin D2 weekly, and vitamin D3 daily, combined with supplemental calcium, in raising serum 25-hydroxyvitamin D [25(OH)D] and lowering PTH concentrations. DESIGN: This was a 6-wk randomized controlled trial. SETTING: The study was conducted at an urban pediatric clinic in Boston. SUBJECTS: Forty otherwise healthy infants and toddlers with hypovitaminosis D [25(OH)D < 20 ng/ml] participated in the study. INTERVENTIONS: Participants were assigned to one of three regimens: 2,000 IU oral vitamin D2 daily, 50,000 IU vitamin D2 weekly, or 2,000 IU vitamin D3 daily. Each was also prescribed elemental calcium (50 mg/kg.d). Infants received treatment for 6 wk. MAIN OUTCOME MEASURES: Before and after treatment, serum measurements of 25(OH)D, PTH, calcium, and alkaline phosphatase were taken. RESULTS: All treatments approximately tripled the 25(OH)D concentration. Preplanned comparisons were nonsignificant: daily vitamin D2 vs. weekly vitamin D2 (12% difference in effect, P = 0.66) and daily D2 vs. daily D3 (7%, P = 0.82). The mean serum calcium change was small and similar in the three groups. There was no significant difference in PTH suppression. CONCLUSIONS: Short-term vitamin D2 2,000 IU daily, vitamin D2 50,000 IU weekly, or vitamin D3 2,000 IU daily yield equivalent outcomes in the treatment of hypovitaminosis D among young children. Therefore, pediatric providers can individualize the treatment regimen for a given patient to ensure compliance, given that no difference in efficacy or safety was noted among these three common treatment regimens. 相似文献
993.
994.
Thrombotic microangiopathy and cytomegalovirus in liver transplant recipients: a case-based review 总被引:2,自引:0,他引:2
K. Ramasubbu T. Mullick A. Koo M. Hussein J.M. Henderson K.D. Mullen R.K. Avery 《Transplant infectious disease》2003,5(2):98-103
Background. Thrombotic microangiopathy (TMA) is a rare but potentially lethal complication encountered in solid organ and bone marrow transplant recipients, requiring rapid recognition, diagnosis, and initiation of therapy. Several potential causes have been identified in this setting, including viral infections and medications. Methods. We report a case of TMA in a liver transplant recipient with active cytomegalovirus (CMV) gastritis. A 41‐year‐old female presented 3 months after liver transplantation with a 5‐week history of nausea, vomiting, anorexia, and diarrhea. CMV serology was donor seropositive and recipient seronegative (D+/R?). The immunosuppressive regimen consisted of tacrolimus, mycophenolate mofetil, and prednisone. Evaluation revealed CMV viremia with a high viral load and intravenous ganciclovir was started. A decline in hemoglobin and platelets with an increase in lactate dehydrogenase (LDH) warranted hematologic evaluation, which revealed findings consistent with microangiopathic hemolytic anemia. Ganciclovir and tacrolimus were discontinued. Intravenous immunoglobulin was administered and daily plasmapheresis was initiated. As the patient's blood counts and LDH started to improve, ganciclovir was cautiously reinstituted. The patient's gastrointestinal symptoms gradually resolved and her blood counts continued to improve with prolonged plasmapheresis (a total of 23 plasmapheresis sessions). Tacrolimus and possibly CMV infection were suspected to be the cause for her TMA, and cyclosporine was substituted. Conclusions. TMA is an important entity in the differential diagnosis of acute hemolytic anemia in liver transplant recipients. Many cases seem to be medication‐induced. However, in treatment‐resistant or relapsing cases, a possibility of concomitant CMV infection should be considered. 相似文献
995.
Avery RK Pohlman BL Mossad SB Goormastic M Longworth DL Kalaycio ME Sobecks RM Andresen SW Kuczkowski E Bernhard L Ostendorf H Wise K Bolwell BJ 《Bone marrow transplantation》2002,30(5):311-314
High-dose etoposide (2 g/m(2)) plus G-CSF is a very effective regimen for peripheral blood progenitor cell (PBPC) mobilization. Unfortunately, neutropenia is common. The infectious complications associated with high-dose etoposide have not been previously described. After noting a high incidence of hospitalizations for neutropenic fever, we began a vigorous prophylactic antibiotic regimen for patients receiving high-dose etoposide plus G-CSF, attempting to reduce infectious complications. Ninety-eight patients underwent etoposide mobilization between December 1997 and June 2000. Three chronological patient groups received: (1) no specific antibiotic prophylaxis (n = 44); (2) vancomycin i.v., cefepime i.v., clarithromycin p.o., and ciprofloxacin p.o. (n = 27); and (3) vancomycin i.v., clarithromycin p.o., and ciprofloxacin p.o. (n = 27). The patients not receiving antibiotic prophylaxis had a 68% incidence of hospitalization for neutropenic fever. In the patients receiving prophylaxis, the incidence was reduced to 26% and 15% respectively, for an overall incidence of 20% (P < 0.001 for comparison between prophylaxed and unprophylaxed groups). We conclude that etoposide mobilization is associated with a significant incidence of neutropenic fever, which can be substantially reduced by a vigorous antimicrobial prophylactic program. 相似文献
996.
R.H. Rubin S.A. Kemmerly D. Conti M. Doran B.M. Murray J.F. Neylan C. Pappas D. Pitts R. Avery M. Pavlakis R. Del Busto D. DeNofrio E.A. Blumberg D.A. Schoenfeld T. Donohue S.A. Fisher J.A. Fishman 《Transplant infectious disease》2000,2(3):112-117
Background: Optimal prophylaxis against cytomegalovirus (CMV) disease for organ transplant patients at risk for primary infection (donor seropositive, recipient seronegative, D+R?) remains to be determined. We hypothesized that prolonged oral ganciclovir therapy following intravenous therapy would provide increased protection. Methods: A total of 155 evaluable D+R? organ transplant recipients from 13 transplant centers were entered into the study: all received intravenous ganciclovir (5 mg/kg/day) for 5–10 days and then either oral acyclovir (400 mg tid) or oral ganciclovir (1 g tid) for an additional 12 weeks. Patients were assigned to their treatment groups at a central randomization site, with a separate randomization scheme for each of the organs transplanted (kidney, heart, or liver). In the case of kidney transplants, the patients were stratified according to source of the kidney (living related vs. cadaveric donor). The primary endpoint was the incidence of CMV disease in the first six months post‐transplant. Results: Treatment with oral ganciclovir was associated with a significant decrease in the incidence of symptomatic disease or viremia when compared with the oral acyclovir group (32% vs. 50%, P<0.05). This difference was most marked in terms of tissue invasive disease: only 3 of 15 symptomatic patients in the ganciclovir group vs. 10 of 21 in the acyclovir group developed tissue‐invasive infection (P<0.05). There was a significant difference in the time to CMV disease or viremia in the two groups: mean time 212±17 days post‐transplant for the acyclovir group vs. 291±13 days for the ganciclovir group (P<0.001). The incidence of allograft rejection was 34% in the ganciclovir group and 46% in the acyclovir group (P=NS). Leukopenia was more common in the ganciclovir group (P<0.05), but in no case did it require drug discontinuation. Ganciclovir resistance did not develop in this study. Conclusion: Prophylaxis with oral ganciclovir following a brief course of intravenous ganciclovir provides useful protection against primary CMV disease. 相似文献
997.
M.H. Yamani R. Avery S. Mawhorter J.B. Young A. McNeill D.J. Cook N.B. Ratiff P. McCarthy & R.C. Starling 《Transplant infectious disease》2001,3(S2):40-43
Hypogammaglobulinemia (HGG) in solid organ transplant (SOT) patients confers an increased risk of opportunistic infections and poorer outcomes. Severe HGG (IgG < 350 mg/dL) after heart transplantation may follow intensification of immunosuppressive therapy and the resultant increased risk of opportunistic infections, particularly cytomegalovirus (CMV) disease. Evaluation of the effects of replacement therapy using intravenous immunoglobulin (CMV-IGIV, CytoGam®) was conducted in cardiac transplant recipients and the data matched with a historical control group. Patients with severe HGG who received pre-emptive replacement therapy had significantly fewer opportunistic infections ( P < 0.001) and episodes of rejection (grade 3; P = 0.03 and grade 2; P = 0.04) compared with the control group. 相似文献
998.
A Antinori T Coenen D Costagiola N Dedes M Ellefson J Gatell E Girardi M Johnson O Kirk J Lundgren A Mocroft A D'Arminio Monforte A Phillips D Raben JK Rockstroh C Sabin A Sönnerborg F De Wolf for the European Late Presenter Consensus working group 《HIV medicine》2011,12(1):61-64
Objectives Across Europe, almost a third of individuals infected with HIV do not enter health care until late in the course of their infection. Surveillance to identify the extent to which late presentation occurs remains inadequate across Europe and is further complicated by the lack of a common clinical definition of late presentation. The objective of this article is to present a consensus definition of late presentation of HIV infection. Methods Over the past year, two initiatives have moved towards a harmonized definition. In spring 2009, they joined efforts to identify a common definition of what is meant by a ‘late‐presenting’ patient. Results Two definitions were agreed upon, as follows. Late presentation: persons presenting for care with a CD4 count below 350 cells/μL or presenting with an AIDS‐defining event, regardless of the CD4 cell count. Presentation with advanced HIV disease: persons presenting for care with a CD4 count below 200 cells/μL or presenting with an AIDS‐defining event, regardless of the CD4 cell count. Conclusion The European Late Presenter Consensus working group believe it would be beneficial if all national health agencies, institutions, and researchers were able to implement this definition (either on its own or alongside their own preferred definition) when reporting surveillance or research data relating to late presentation of HIV infection. 相似文献
999.
1000.